Fangda assists Brattea in completing its high-value series-D financing_News_About

Fangda assists Brattea in completing its high-value series-D financing

2024 / 04 / 24

Fangda represented Shanghai Brattea Medical Technology Co., Ltd. (“Brattea”) in its series D investment. The transaction was closed in March 2024. Fangda team on this deal was led by partner Luo Ke, and the team members included Elaine Li and Joshua Tsui. Fangda assisted in the drafting and negotiation of transaction documents and the closing process. Brattea mainly engages in the R&D of medical devices in relation to nerve radiofrequency ablation, including Renal denervation (RDN) for hypertension.

Previous：Fangda represents Mindray in its strategic acquisition of the controlling shareholding right of APT, a listed company on the STAR Market Board

Next：Fangda assisted Voneseals in completing a material asset restructuring transaction through equity acquisition of Shanghai Garnor

2026 / 05 / 13

Fangda assists TCL in multijurisdictional restructuring of Maxeon Solar

2026 / 04 / 28

Fangda advises Lightelligence on becoming the first optoelectronic hybrid computing power company to successfully list on the Main Board of the HKEX under Chapter 18C

2026 / 04 / 27

Fangda Advises UBTECH on Acquisition of Controlling Stake in Fenglong

2026 / 04 / 23

Fangda Assists the Acquisition by Beijing BSCOMC E-TOWN CBC Industrial Investment Fund of the Controlling Interests in Pediatrix Therapeutics

2026 / 04 / 21

Fangda Assists TJ Biopharma on Entering into Collaboration Agreement with Biogen for the Exclusive Rights of Felzartamab in the Greater China Region